WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H462701
CAS#: 60114-68-3
Description: Thromboxane A3 is a member of the family of lipids known as eicosanoids. The distinguishing feature of thromboxanes is a 6-membered ether-containing ring.Thromboxane is named for its role in clot formation.
Hodoodo Cat#: H462701
Name: Thromboxane A3
CAS#: 60114-68-3
Chemical Formula: C20H30O5
Exact Mass: 350.21
Molecular Weight: 350.455
Elemental Analysis: C, 68.55; H, 8.63; O, 22.83
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: TXA3;
IUPAC/Chemical Name: (Z)-7-((1S,3R,4S,5S)-3-((S,1E,5E)-3-hydroxyocta-1,5-dien-1-yl)-2,6-dioxabicyclo[3.1.1]heptan-4-yl)hept-5-enoic acid
InChi Key: NMZKLLJQNNTBRJ-GIGDAOFJSA-N
InChi Code: InChI=1S/C20H30O5/c1-2-3-6-9-15(21)12-13-17-16(18-14-20(24-17)25-18)10-7-4-5-8-11-19(22)23/h3-4,6-7,12-13,15-18,20-21H,2,5,8-11,14H2,1H3,(H,22,23)/b6-3+,7-4-,13-12+/t15-,16+,17+,18-,20+/m0/s1
SMILES Code: CC/C=C/C[C@@H](/C=C/[C@H]1O[C@H]2C[C@@H]([C@@H]1C/C=C\CCCC(O)=O)O2)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 350.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Fischer S, Weber PC. Thromboxane A3 (TXA3) is formed in human platelets after dietary eicosapentaenoic acid (C20:5 omega 3). Biochem Biophys Res Commun. 1983 Nov 15;116(3):1091-9. doi: 10.1016/s0006-291x(83)80254-x. PMID: 6316965.
2: Shimizu T, Yokotani K. Effects of centrally administered prostaglandin E(3) and thromboxane A(3) on plasma noradrenaline and adrenaline in rats: comparison with prostaglandin E(2) and thromboxane A(2). Eur J Pharmacol. 2009 Jun 2;611(1-3):30-4. doi: 10.1016/j.ejphar.2009.03.057. Epub 2009 Apr 1. PMID: 19344706.
3: Fischer S, Weber PC. Thromboxane (TX)A3 and prostaglandin (PG)I3 are formed in man after dietary eicosapentaenoic acid: identification and quantification by capillary gas chromatography-electron impact mass spectrometry. Biomed Mass Spectrom. 1985 Sep;12(9):470-6. doi: 10.1002/bms.1200120905. PMID: 2996649.
4: Sørensen JD, Olsen SF, Pedersen AK, Boris J, Secher NJ, FitzGerald GA. Effects of fish oil supplementation in the third trimester of pregnancy on prostacyclin and thromboxane production. Am J Obstet Gynecol. 1993 Mar;168(3 Pt 1):915-22. doi: 10.1016/s0002-9378(12)90845-5. PMID: 8456902.
5: Smith WL. Cyclooxygenases, peroxide tone and the allure of fish oil. Curr Opin Cell Biol. 2005 Apr;17(2):174-82. doi: 10.1016/j.ceb.2005.02.005. PMID: 15780594.
6: Moncada S, Vane JR. The role of prostacyclin in vascular tissue. Fed Proc. 1979 Jan;38(1):66-71. PMID: 215463.
7: Hamazaki T, Fischer S, Schweer H, Meese CO, Urakaze M, Yokoyama A, Yano S. The infusion of trieicosapentaenoyl-glycerol into humans and the in vivo formation of prostaglandin I3 and thromboxane A3. Biochem Biophys Res Commun. 1988 Mar 30;151(3):1386-94. doi: 10.1016/s0006-291x(88)80516-3. PMID: 3281674.
8: Villalobos ME, Sánchez-Muniz FJ, Acín MT, Vaquero MP, Higueras FJ, Bastida S. Similitudes, diferencias y agonismos en los efectos pleiotrópicos de las estatinas y los ácidos grasos omega-3 [Similarities, differences and agonisms of pleiotropic effects of statins and omega-3 fatty acids]. Nutr Hosp. 2010 Nov- Dec;25(6):889-909. Spanish. PMID: 21519759.
9: Knapp HR, Reilly IA, Alessandrini P, FitzGerald GA. In vivo indexes of platelet and vascular function during fish-oil administration in patients with atherosclerosis. N Engl J Med. 1986 Apr 10;314(15):937-42. doi: 10.1056/NEJM198604103141501. PMID: 3007982.
10: Needleman P, Minkes M, Raz A. Thromboxanes: selective biosynthesis and distinct biological properties. Science. 1976 Jul 9;193(4248):163-5. doi: 10.1126/science.945611. PMID: 945611.
11: Krämer HJ, Stevens J, Grimminger F, Seeger W. Fish oil fatty acids and human platelets: dose-dependent decrease in dienoic and increase in trienoic thromboxane generation. Biochem Pharmacol. 1996 Oct 25;52(8):1211-7. doi: 10.1016/0006-2952(96)00473-x. PMID: 8937428.
12: Tschopp TB, Muggli R. Fischöl bei Thrombose und Arteriosklerose [Fish oil in thrombosis and arteriosclerosis]. Schweiz Med Wochenschr. 1990 Mar 17;120(11):372-8. German. PMID: 2181643.
13: Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet. 1978 Jul 15;2(8081):117-9. doi: 10.1016/s0140-6736(78)91505-2. PMID: 78322.
14: Gallet C, Rosa JP, Habib A, Lebret M, Lévy-Tolédano S, Maclouf J. Tyrosine phosphorylation of cortactin associated with Syk accompanies thromboxane analogue-induced platelet shape change. J Biol Chem. 1999 Aug 13;274(33):23610-6. doi: 10.1074/jbc.274.33.23610. PMID: 10438543.
15: Storlien LH, Kriketos AD, Calvert GD, Baur LA, Jenkins AB. Fatty acids, triglycerides and syndromes of insulin resistance. Prostaglandins Leukot Essent Fatty Acids. 1997 Oct;57(4-5):379-85. doi: 10.1016/s0952-3278(97)90414-2. PMID: 9430382.
16: Hamazaki T, Fischer S, Urakaze M, Sawazaki S, Yano S. Comparison of the urinary metabolites of prostacyclin and thromboxane of the 2- and 3-series in a Japanese fishing and a Japanese farming village. Prostaglandins. 1986 Nov;32(5):655-64. doi: 10.1016/0090-6980(86)90188-7. PMID: 3029810.
17: Wada M, DeLong CJ, Hong YH, Rieke CJ, Song I, Sidhu RS, Yuan C, Warnock M, Schmaier AH, Yokoyama C, Smyth EM, Wilson SJ, FitzGerald GA, Garavito RM, Sui de X, Regan JW, Smith WL. Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem. 2007 Aug 3;282(31):22254-66. doi: 10.1074/jbc.M703169200. Epub 2007 May 22. PMID: 17519235.
18: von Schacky C, Fischer S, Weber PC. Long-term effects of dietary marine omega-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans. J Clin Invest. 1985 Oct;76(4):1626-31. doi: 10.1172/JCI112147. PMID: 2997286; PMCID: PMC424148.
19: Grimminger F, Mayer K, Krämer HJ, Stevens J, Walmrath D, Seeger W. Differential vasoconstrictor potencies of free fatty acids in the lung vasculature: 2-versus 3-series prostanoid generation. J Pharmacol Exp Ther. 1993 Oct;267(1):259-65. PMID: 8229753.
20: Knapp HR, FitzGerald GA. The antihypertensive effects of fish oil. A controlled study of polyunsaturated fatty acid supplements in essential hypertension. N Engl J Med. 1989 Apr 20;320(16):1037-43. doi: 10.1056/NEJM198904203201603. PMID: 2648152.
